發(fā)布時間：2019-08-02 10:57

【摘要】：目的:探討重組人干擾素α2b陰道泡騰膠囊結合射頻消融術治療宮頸糜爛合并人乳頭瘤病毒(HPV)亞臨床感染(SPI)的臨床療效及安全性。方法:選取2014年7月-2015年8月我院婦科門診收治的宮頸糜爛合并SPI患者207例,按隨機數字表法分為A、B、C組,各69例。A組患者于月經周期結束3 d后給予重組人干擾素α2b陰道泡騰膠囊80萬IU,陰道后穹窿給藥,qd,10 d為1個療程,治療3個療程;B組患者進行射頻消融術治療;C組患者采用同等劑量重組人干擾素α2b陰道泡騰膠囊結合射頻消融術治療。所有患者隨訪半年。評價3組患者臨床療效及B、C組患者術后創(chuàng)面愈合率,術后2周臨床癥狀消失率、并發(fā)癥發(fā)生率,并記錄不良反應。結果:B、C組患者宮頸糜爛治療有效率分別為94.20%、98.55%,顯著高于A組的62.32%;C組患者SPI有效率為92.75%,顯著高于B組的69.57%和A組的53.62%;C組患者HPV感染有效率為86.96%,顯著高于B組的63.77%,差異均有統(tǒng)計學意義(P0.05)。B組患者術后4、6、8周創(chuàng)面愈合率分別為10.14%、43.48%、97.10%,C組患者分別為52.17%、92.75%、100.00%;C組患者術后4、6周創(chuàng)面愈合率顯著高于B組,差異有統(tǒng)計學意義(P0.05)。C組患者術后2周陰道出血和排液等臨床癥狀消失率為81.16%,顯著高于B組的43.48%,差異有統(tǒng)計學意義(P0.05)。B、C組患者并發(fā)癥發(fā)生率分別為11.60%、4.35%,組間差異無統(tǒng)計學意義(P0.05)。兩組患者均未見明顯不良反應發(fā)生。結論:重組人干擾素α2b陰道泡騰膠囊結合射頻消融術治療宮頸糜爛合并SPI療效較好,創(chuàng)面愈合時間短,且安全性較好。
[Abstract]:Objective: to investigate the clinical efficacy and safety of recombinant human interferon 偽 2b vaginal effervescent capsule combined with radiofrequency ablation in the treatment of cervical erosion complicated with subclinical infection of human papillomavirus (HPV). Methods: from July 2014 to August 2015, 20 patients with cervical erosion complicated with SPI were randomly divided into two groups: group A (n = 69) and group C (n = 69). After 3 days of menstrual cycle, patients in group A were given recombinant human interferon 偽 2b vaginal effervor capsule 800000 IU, posterior vaginal fornix, qd,10 d was a course of treatment for 3 courses, group B was treated with radiofrequency ablation, and group B was treated with radiofrequency ablation. Group C patients were treated with the same dose of recombinant human interferon 偽 2b vaginal effervescent capsule combined with radiofrequency ablation. All patients were followed up for half a year. To evaluate the clinical efficacy of the three groups and the wound healing rate of group C, the disappearance rate of clinical symptoms and the incidence of complications 2 weeks after operation, and to record the adverse reactions. Results: the effective rate of cervical erosion in group C was 94.20% and 98.55% respectively, which was significantly higher than that in group A (62.32%) and group C (92.75%), which was significantly higher than that in group B (6957%) and group A (53.62%). The effective rate of HPV infection in group C was 86.96%, which was significantly higher than that in group B (63.77%). The effective rate of HPV infection in group C was significantly higher than that in group B (P < 0.05). The wound healing rate in group C was 10.14%, 43.48% and 9710%, respectively, and that in group C was 52.17%, 92.75% and 100.00%, respectively. At 4 weeks after operation, the wound healing rate in group C was significantly higher than that in group B, the difference was statistically significant (P 0.05). The disappearance rate of vaginal bleeding and drainage in group). C was 81.16%, which was significantly higher than that in group B (43.48%) (P 0.05). The incidence of complications in group B and C was 11.60% and 4.35% respectively, and there was no significant difference between the two groups (P 0.05). No obvious adverse reactions were found in both groups. Conclusion: recombinant human interferon 偽 2b vaginal effervescent capsule combined with radiofrequency ablation is effective in the treatment of cervical erosion complicated with SPI, and the wound healing time is short and safe.
【作者單位】： 承德醫(yī)學院附屬醫(yī)院婦科;承德醫(yī)學院基礎醫(yī)學院;
【基金】：承德市科學技術研究與發(fā)展計劃項目(No.20122148,20142031)
【分類號】：R711.33;R737.33

【相似文獻】

相關期刊論文 前2條

1 馮余寬,彭秀瓊,朱聯,梅蓉,劉珊玲;奧平栓治療女性生殖道HPV亞臨床感染的臨床試驗研究[J];實用婦產科雜志;2003年04期

2 魏惠珍;劉蕊;丁曉萍;;宮頸上皮內瘤樣病變與HPV亞臨床感染的中藥干預研究[J];中國誤診學雜志;2007年25期

，

本文編號：2522071